Robert Koch Gold Medal 2016 to Kai Simons

November 07, 2016

Kai Simons, founding director of the Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG) and managing director of Lipotype GmbH, receives the Robert Koch Medal in Gold for his lifetime achievements, in particular for his characterization of membrane-forming lipids and the development of the lipid raft concept. The Award Ceremony takes place on Friday, November 4th 2016 at the Berlin-Brandenburg Academy of Sciences and Humanities.

Honoured with the Robert Koch Medal in Gold: Kai Simons.

Simons has spent his life studying cell membranes, wafer-thin bilayers of fat molecules (“lipids”) that surround each cell of the human body and most cellular compartments. Kai Simons discovered floating nano-assemblies of lipids and proteins in the lipid bilayer of cell membranes that reminded him of the log rafts which Finnish lumberjacks used as platforms drifting downstream – hence the name “lipid rafts”. Simons demonstrated the fascinating properties of these rafts: They are fluid and dynamic, they can appear and disappear. Lipid rafts do not only play a significant role as functional platforms in signal transduction and many other membrane processes, but they are also involved in many diseases such as Alzheimer’s disease and AIDS.

“I am overwhelmed!” says laureate Kai Simons. “This award is inspiring and I hope that lipids and lipidomics will continue to stimulate molecular life science research, but ultimately also help to improve health and clinical performance”.

Kai Simons started the Cell Biology Program at the European Molecular Biology Laboratory (EMBL) in Heidelberg and moved to Dresden in 2001 to build up the Max Planck Institute of Molecular Cell Biology and Genetics. Kai Simons received numerous honors, including the Keith Porter Lecturer of the American Society for Cell Biology. He received a honorary degree from the Universities of Geneva, Oulu and Kuopio (Finland), and Leuven (Belgium). Kai Simons is also a serial entrepreneur. His current venture, Lipotype GmbH, has developed a novel lipidomics platform for personalized medicine, functional foods as well as for novel dermatological and cosmetic products. Most importantly, the blood lipidomes that Lipotype can provide promise diagnostic breakthroughs for personalized health and medicine.

The Robert Koch Foundation, founded in 1907, is a non-profit foundation for the promotion of medical progress. It supports basic scientific research in the field of infectious diseases, as well as exemplary projects designed to address medical and hygienic problems. The Foundation annually awards the Robert Koch Gold Medal in recognition of the outstanding life’s work of a scientist.

About Professor Kai Simons

Kai Simons received his MD degree from the University of Helsinki. He then conducted postdoctoral research at Rockefeller University in New York. In 1967, he was Principal Investigator of the Finnish Medical Research Council at the University of Helsinki. In 1975, he moved to the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, where he started the Cell Biology Program, which became the focal point for molecular cell biology in Europe. In 2001, Kai Simons moved to Dresden to build up the Max Planck Institute of Molecular Cell Biology and Genetics. This institute became an internationally recognized center in its area of research. Simons’ recent research focuses on cell membrane organization and function. Kai Simons has pioneered the concept of lipid rafts as a membrane organizing principle, based on the phase-separating capabilities of sphingolipids and cholesterol in cell membranes. Kai Simons is a foreign member of the National Academy of Sciences, USA, and was the President of the European Life Scientist Organization. From 2007 to 2008, Simons was co-director of the Shanghai Institute for Advanced Studies of the Chinese Academy of Science. His biotech experience includes co-founding the Biotech-Start-up Jado Technologies, Lipotype GmbH and membership in the scientific advisory boards of Biogen and Sanofi.

FF/HR

Go to Editor View